This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody & ADC Summit At ChinaBio
Shanghai, China
Kerry Hotel Pudong, Shanghai, ChinaApril 28–29, 2026
Book Now
Menu
Book
Key Sessions
Jan van de Winkel, PhD
Next-generation Antibody Therapeutics for Cancer
Genmab
Shan Jiang, PhD
Racing for First-in-Class and Best-in-Class
Hansoh Pharma
keyboard_arrow_right

Apr 28 - CT (China Time, GMT+08:00)

keyboard_arrow_leftSearch & Filter
search
Apr 28 - CT (China Time, GMT+08:00)
search
Showing 1 of 1 Streams
08:00 - 08:55
Registration and Morning Coffee
08:55 - 09:00
Chairperson’s Remarks
09:00 - 09:45
Next-generation Antibody Therapeutics for Cancer
  • Jan van de Winkel, PhD - President and CEO, Genmab
09:45 - 10:30
Racing for First-in-Class and Best-in-Class
  • Shan Jiang, PhD - Chief Technology Officer, Hansoh Pharma
Showing 1 of 1 Streams
10:30 - 11:15
Networking Refreshment Break with Poster and Exhibit Viewing
Showing 1 of 1 Streams
11:15 - 12:00
Panel Discussion: East Meets West: China's Market Dynamics and Global Investment Trends Shaping the Future of ADC Therapies
  • Cong Xu, MD, PhD - Managing Director, Lilly Asia Ventures
  • Zhizhong Yao, PhD - Partner, Sofinnova Partners
12:00 - 12:30
From Clinical to Commercial- CMC and Regulatory Challenges in Late-Stage Development of ADC Products
  • Jian Zhang, PhD - Acting CEO, BioDlink Biopharm
Showing 1 of 1 Streams
12:30 - 13:40
Networking Luncheon
Showing 2 of 2 Streams
13:40 - 13:45
Chairperson’s Remarks
13:45 - 14:15
Combining Bispecific T-cell Engagers and Costimulatory Agonist Antibodies: An "Off-the-Shelf" Approach for Cancer Therapy
  • Sara Colombetti, PhD - Head of Translational Pharmacology, Roche Oncology pRED, F. Hoffmann-La Roche AG
14:15 - 14:45
Folding-mediated Secretion of Pure Bispecific Antibodies
  • Adam Zwolak, PhD - Director, Biologics Discovery, Johnson & Johnson Innovative Medicine
14:45 - 15:15
Sponsored Scientific Briefing
13:40 - 13:45
Chairperson’s Remarks
13:45 - 14:15
New ADC Payload: Antibody Drug Conjugates with a Novel Protein Translation Inhibitor Payload
  • Tara Arvedson, PhD - Chief Scientific Officer, Hexagon Bio
14:15 - 14:45
Duality Next-generation Novel Payload Technologies
  • Haiqing Hua, PhD - Senior Vice President and Head of Drug Discovery, DualityBio
14:45 - 15:15
Sponsored Scientific Briefing
Showing 1 of 1 Streams
15:15 - 16:00
Networking Refreshment Break with Poster and Exhibit Viewing
Showing 2 of 2 Streams
16:00 - 16:30
The MultipleBody and AccuBody Enabled Development of Multi-Specific Biotherapeutics for Unmet Medical Needs
  • Yongliang Fang, PhD - COO, Doer Biologics
16:30 - 17:00
Human Antibody Discovery and Engineering: The Adimab Way
  • Aaron Sato, PhD - Chief Strategy Officer, Adimab
17:00 - 17:30
End of Day 1 - Transport to Gala Reception
16:00 - 16:30
Harnessing the Therapeutic Promise of Multi-payload ADCs
  • Jerome Boyd-Kirkup, PhD - Chief Scientific Officer and Co-Founder, Callio Therapeutics
16:30 - 17:00
Highly Efficacious and Tolerated Multi-payload ADCs Assembled in One step without Any Antibody Engineering
  • Filippo Mulinacci, PhD - Chief Business Officer, Araris Biotech
17:00 - 17:30
End of Day 1 - Transport to Gala Reception
Showing 1 of 1 Streams
17:30 - 19:30
Gala Networking Reception - ATLATL Innovation Center
Apr 27
NextApr 29
Filter
Streams
Formats
Choose Day